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Abstract. The (Müller et al. 1977 , for a review), but data in humans are scanty, partly conflicting and chiefly obtained in epileptic subjects, treated with barbitu¬ rates for clinical purposes (London 1980 (1 ng = 2 µ ) and 2nd IRP. Intra-assay variations were smaller than 5 % for all hormones. Method sensitivity was 1.4 ng/ml for Prl, 0.15 ng/ml for GH and 1.6 µ /ml for LH.
PB was determined in sera by the gasliquid Chromato¬ graphie method (Kupferberg 1970 (Table 3 ).
In Table 4 the mean values of Prl and GH obtained in each subject during sleep or during waking periods are reported. From these data the corresponding S/W r indices have been calculated.
It can be seen that in PB series the night levels of the two hormones in all subjects are consistently lower than those in the placebo series. The differ¬ ence attains significance (P < 0.05) only for Prl.
The PB effect on nocturnal Prl secretion is also shown by the S/W r, which is significantly dimi¬ nished (P < 0.05).
Discussion
The PB concentrations in serum obtained after a single oral dose and their fluctuations during the observation time are consistent with the pharmacokinetics of the drug and its distribution in tissues (Harvey 1980) . PB serum levels attained in our study are lower than those inducing sedation or antiepileptic ef¬ fects (Harvey 1980) . In spite of the small single PB doses used, we found modifications in the wake-time EEG spectral analysis, consisting of an increase in fast frequency components, in agreement with data by Sannita et The LH increase observed in chronically treated epileptics is thought to depend on changes in the bound-free testosterone ratio induced by longterm AED therapy (Toone et al. 1980) . These data are hardly comparable to our obser¬ vations, because of the differing experimental de¬ signs.
In experimental animals, pentobarbital (PTB) induces an inhibition of Prl secretion, followed by a rise that diminishes after 24-72 h (Wuttke et al. 197l; Borreletal. 1978) .
Moreover, in cycling female rats barbiturates delay ovulation and in ovariectomized rats LH levels are decreased (Arendash & Gallo 1978; Borreletal. 1978; Kalraetal. 1980 ).
The pharmacological actions of PB on the nerv¬ ous system are still uncertain (Nicoli 1978; Prichard 1980) , so that the inhibition of Prl and GH secre¬ tion we observed is not easily explainable. Changes in the endocrine indices studied induced by PB possibly reflect an interference with the neurotransmitter-mediated mechanisms of adenopituitary regulation (Müller et al. 1977) .
No direct information is available about PB ac¬ tion on hypothalamic dopamine (DA), the main neurotransmitter involved in Prl and GH controls (Müller et al. 1977) . In ovariectomized rats PTB does not affect DA turnover in the mediobasal and preoptic nuclei, while a decrease of norepinephrine concentration occurs (Kalra et al. 1980 ).
On the other hand, depressant barbiturates in¬ duce a prolongation of the sedative effects of gamma-aminobutyric acid (GABA) (Nicoli 1978) , possibly interacting at the GABA-receptor level (Olsen 1981) . A GABAergic antiepileptic drug, sodium valproate, seems to inhibit Prl secretion (Melis et al. 1982) . Nevertheless the effects of GABA on GH secretion are still debatable (Racagni et al. 1982 (Kapen et al. 1980) . Therefore, the effect of PB on Prl and GH sleepconnected secretion may be interpreted in view of an impairment of 5-HT release, observed after administration of barbiturates (Bonnycastle et al. 1962 ). The decrease of serotoninergic effect might be mediated by a GABAergic activation (Colling et al. 1982 (Nicoli 1978 ). An effect on mem¬ brane properties, influencing for instance ion ex¬ changes involved in adenohypophyseal secretion, such as calcium ions, is apparent only at very high barbiturate concentrations (Nicoli 1978 
